| abstract |
The purpose of the present invention is to provide a complete human anti-human TfR antibody that specifically recognises human TfR, inhibits the survival and multiplication of cancer cells in which TfR is overexpressed, and exhibits no immunogenicity in humans. The antibody that specifically responds to human TfR respectively contains as the heavy chain first complementarity determining region (VHCDR1), the heavy chain second complementarity determining region (VHCDR2), and the heavy chain third complementarity determining region (VHCDR3), amino acid sequences represented by any of the following SEQ ID NOs.: 1-3, 7-9, 13-15, 19-21, 25-27, 31-33, 37-39, 43-45, 49-51, 55-57, 61-63, 67-69, 73-75, 79-81, 85-87, 91-93, 97-99, 103-105, 109-111, 115-117. |